+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Tryp Therapeutics Inc Ordinary Shares

(OTC:TRYPF)

Intraday

$0.0562

0[0.00%]

15 minutes delayed

Perks Buy Compare Brokers

$0.0562

0[0.00%]

Last update: 3:17PM Get Real Time Here

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Tryp Therapeutics Inc Ordinary Shares Stock (OTC:TRYPF)

Tryp Therapeutics Inc Ordinary Shares Stock (OTC: TRYPF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, April 25, 2024

Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing
Patricio Liddle - Apr 25, 2024, 11:05AM

Friday, January 12, 2024

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Lara Goldstein - Jan 12, 2024, 4:55PM

Monday, January 08, 2024

Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
Lara Goldstein - Jan 8, 2024, 4:22PM

Wednesday, July 19, 2023

Psyched: NDAA Amendments Blocked, National Practitioners Network, Marijuana In Jackie Kennedy's Garden And More
Lara Goldstein - Jul 19, 2023, 6:43PM

Thursday, July 13, 2023

Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital
Lara Goldstein - Jul 13, 2023, 3:48PM

Tuesday, June 13, 2023

Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
Lara Goldstein - Jun 13, 2023, 2:05PM

Wednesday, May 24, 2023

Tryp Submits IND Application To FDA For Clinical Trial Of Psilocybin-Assisted Psychotherapy In Patients With IBS
Vuk Zdinjak - May 24, 2023, 10:57AM

Monday, May 01, 2023

Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Lara Goldstein - May 1, 2023, 7:06PM

Thursday, April 27, 2023

Tryp Therapeutics Secures $1.6M Via Oversubscribed Private Placement
Vuk Zdinjak - Apr 27, 2023, 8:16AM

Friday, April 14, 2023

EXCLUSIVE: In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
Joana Scopel - Apr 14, 2023, 10:51AM

Tuesday, April 04, 2023

Therapists At Mass General Hospital Prepared To Assist IBS Patients With Psilocybin Therapy
Lara Goldstein - Apr 4, 2023, 4:47PM

Monday, April 03, 2023

What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
Javier Hasse - Apr 3, 2023, 2:05PM

Tuesday, January 10, 2023

Psyched: NY Discusses Regulations, MDMA For PTSD Aims For Legalization, Shrooms For Eating Disorders & More
Lara Goldstein - Jan 10, 2023, 1:16PM

Thursday, January 05, 2023

Treating Binge Eating Disorder With Magic Mushrooms: Phase 2 Clinical Trial Gets Thumbs Up
Lara Goldstein - Jan 5, 2023, 5:29PM

Tuesday, January 03, 2023

Business & Academia Join Forces To Study Magic Mushroom Therapy For IBS Patients
Lara Goldstein - Jan 3, 2023, 2:50PM

Tuesday, October 04, 2022

This Psychedelics Company Is Patenting Its Psilocin And Psilocybin Delivery Route
Lara Goldstein - Oct 4, 2022, 4:02PM

Monday, September 26, 2022

Is Psilocybin Therapy A Potential Treatment For Fibromyalgia & Binge Eating Disorder?
Lara Goldstein - Sep 26, 2022, 3:52PM

Wednesday, September 14, 2022

Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma
Lara Goldstein - Sep 14, 2022, 7:02PM

Wednesday, June 15, 2022

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Natan Ponieman - Jun 15, 2022, 12:32PM

Thursday, June 09, 2022

Clinical Trials Of Psilocybin Treatment For Overeating Disorder Are Ready, Here's What Results Show So Far
Lara Goldstein - Jun 9, 2022, 10:26PM

Thursday, June 02, 2022

These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
Natan Ponieman - Jun 2, 2022, 3:51PM

Monday, May 02, 2022

Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
Natan Ponieman - May 2, 2022, 5:04PM

Thursday, April 28, 2022

Could Magic Mushrooms Be A Solution For Overeating? New Clinical Trial Intends To Find Out
Natan Ponieman - Apr 28, 2022, 3:03PM

Thursday, December 23, 2021

FDA Approves Psilocybin For Binge Eating Study By Tryp Therapeutics
Natan Ponieman - Dec 23, 2021, 3:18PM

Monday, November 08, 2021

Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Natan Ponieman - Nov 8, 2021, 10:52AM

Monday, October 18, 2021

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman - Oct 18, 2021, 1:37PM

Wednesday, October 13, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman - Oct 13, 2021, 4:25PM

Monday, August 30, 2021

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Natan Ponieman - Aug 30, 2021, 11:21AM

Thursday, August 26, 2021

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021
Benzinga Insights - Aug 26, 2021, 10:04AM
Ladenburg Thalmann Initiates Coverage On Tryp Therapeutics with Buy Rating
Benzinga Newsdesk - Aug 26, 2021, 8:57AM

Monday, July 26, 2021

Psyched: Cybin And Field Trip Head To Wall Street, AOC Pushes For Federal Psychedelics Research, Off-Label Ketamine Covered By Insurance In Canada
Natan Ponieman - Jul 26, 2021, 8:02AM

Monday, July 12, 2021

Psyched: Numinus, MindMed, Cybin Reach Milestones, Harvard To Study Psychedelics Law, Michael Pollan Dives Into Mescaline
Natan Ponieman - Jul 12, 2021, 8:41AM

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved